Video

Dr. Dorff on state of second-line treatment for metastatic urothelial cancer

Author(s):

Urology Times staff

Tanya Dorff, MD, discusses the currently available therapeutic options for patients with metastatic urothelial cancer who have progressed on frontline treatment. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
4 experts in this video
4 experts in this video
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
4 experts in this video
4 experts in this video
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Related Content
From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance
June 16th 2025

From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance

Anne K. Schuckman, MD Hannah Clarke
Anne K. Schuckman, MD, describes the growing number of options in NMIBC and the impact of these therapies on clinical practice.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
June 12th 2025

FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC

Hannah Clarke
The approval is supported by findings from the phase 3 ENVISION trial.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
June 9th 2025

En bloc resection of bladder tumor: Is it the way forward?

Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery)
"As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).
Survey: New NMIBC treatments face slow uptake
June 2nd 2025

Survey: New NMIBC treatments face slow uptake

Benjamin P. Saylor
Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.
© 2025 MJH Life Sciences

All rights reserved.